EHA Grants Hall of Fame

Quality of Life and Symptoms

The goals of the SWG are:

To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.

Position of EHA on the Harmonization of Training and Education in Europe

 

The challenge
Education and training are largely national competencies.

How malignant cells in patients with Chronic Lymphocytic Leukemia escape T cell recognition and attack

T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells.

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders in EU is €23 billion

In Europe blood disorders affect around 80 million people. The total cost of blood disorders consists of healthcare expenditure (€15. 6 billion), productivity loss due to illness and mortality (€5. 6 billion), and the costs of informal care (€1.

Congratulations to the 2021 Research Grant winners!

The Hague, 2 June 2021 –EHA congratulates nine talented researchers in hematology on their receipt of the EHA Research Grants 2021 after a rigorous selection process.